RCS - Induction Healthcare - RFL selects Induction to deliver patient portal

Induction HealthcareAnnouncement

13/01/2021 07:00

RNS Number : 4585L
  
Induction Healthcare Group PLC 
  
13 January 2021
  
 

Induction Healthcare Group PLC
 
("Induction", the "Company", or the "Group")
 
Royal Free selects Induction to deliver new patient portal
 
- Improving patient access to digital services
- High adoption since launch, with over 50,000 patients registered 
 
Induction, a leading healthcare technology company that helps digitally transform hospitals, announces a contract with the Royal Free London NHS Foundation Trust ("RFL"). Induction Zesty, a leading provider of patient portals to NHS Hospitals, has delivered the My RFL Care patient portal as the first phase of an ambitious roadmap for RFL's digital patient services in the next two years. 
 
The My RFL Care portal launched in August 2020 and has had significant traction with over 50,000 patients registering and using the service in the first few months. 250,000 patients are expected to adopt the service in the first year.
 
The RFL combines globally recognised clinical expertise with local and friendly hospital care to represent the best of the NHS. The trust is a world-leader in a range of specialist services, including infectious diseases, immunology, kidney and liver transplantation, cancer care, plastic surgery and vascular surgery. The trust also runs internationally recognised clinical research programmes and is a leading teaching hospital. 
 
Induction Zesty are committed to transforming clinical pathways in acute hospitals by putting the right technology in the hands of the patient. This patient-centric, technology-driven vision delivers superior patient outcomes while reducing whole-system costs for hospitals. It alleviates the strain on hospital resources and embeds a long-term foundation for future improvements.
 
 
Induction Joint CEO and Zesty founder, James Balmain, said: 
"Partnering with Royal Free London, one of the largest and most respected hospitals in the UK, is an important milestone for Induction Zesty. In just a few months, tens of thousands of patients have successfully registered and used the platform. We look forward to supporting the Royal Free London in delivering further enhanced functionality for their patient portal over the coming months."
 
RFL Group Chief Digital Officer, Glenn Winteringham, said: 
"The Induction Zesty team have done an outstanding job of delivering the first phase of our digital programme in just eight weeks which gives me a lot of confidence I have the right digital partner to deliver our ambitious roadmap in the future. The early results are very impressive with a high adoption rate among our patients. I am excited by the potential this innovation has to make a real difference to our patients as we address the overhang from the COVID-19 pandemic."
 
- ENDS -
 
 
ENQUIRIES 
 



Induction Healthcare


Via FTI Consulting




Dr Hugo Stephenson, Joint Chief Executive Officer








James Balmain, Joint Chief Executive Officer


















Numis Securities (Nominated Adviser and Broker)


+44 (0) 207 260 1000




James Black / Freddie Barnfield / Huw Jeremy / Matthew Jones


















FTI Consulting


+44 (0) 203 727 1000




Jamie Ricketts / Elena Kalinskaya / Sam Purewal 







 
 
About Induction
 
Induction (INHC.LSE) is a UK-based leading healthcare technology company enabling the digital transformation of secondary care. This is done by rolling up smaller solutions that are loved by doctors, hospital staff and patients and giving those solutions the infrastructure, credibility and interoperability they need to achieve commercial success at scale.
 
Over 190,000 hospital doctors across multiple territories, including the UK, Ireland, Australia and South Africa - as well as a rapidly growing cohort of over 140,000 patients - choose to use Induction products over traditional methods of managing care.
 
Induction helps healthcare professionals deliver better care more efficiently via a suite of technology platforms, including Induction Switch, Induction MicroGuide, Induction Zesty and Induction HealthStream.
 
Induction Zesty is a leading provider of patient portals to NHS Hospitals in the UK, enabling hospital patients to manage their care direct from their smartphone. Induction Zesty removes the friction from everyday health related tasks, like booking and managing appointments, enabling remote patient monitoring, and sharing copies of electronic medical records.
 
Induction HealthStream is a proprietary data integration platform that reads and writes patient demographic, appointment and clinical record data between a growing number of hospital EHR systems and the Induction platforms.
 
Induction Switch is the number one healthcare collaboration app in the UK, used by the majority of hospital doctors within the NHS. The app helps to increase productivity and enhance communication by securely sharing phone numbers and bleeps, bookmarks, documents and messages in a clinical setting.
 
Induction MicroGuide provides medical organisations, including most hospital trusts within the NHS, with the ability to collaboratively create, edit, and publish their own local medical guidelines in a secure and locally administrated environment. 
 
About Royal Free London NHS Foundation Trust
 
The Royal Free began as a pioneering organisation and continues to play a leading role in the care of its patients. The Royal Free's mission is to provide world class expertise and local care.  Established in 1828 by William Marsden, a newly qualified surgeon shocked that he could not find treatment for a penniless young woman, the Royal Free's founding principle was that they would take in anyone who needed treatment - the first hospital in London to do so and the only London hospital to stay open during the 19th-century cholera epidemics.  
 
In the 21st century, the Royal Free London continues to lead improvements in healthcare and is proud to have some of the best clinical outcomes in the country. 
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAMZGMMNZZGMZM